Literature DB >> 33488669

The Clinical Significance of DNA Damage Repair Signatures in Clear Cell Renal Cell Carcinoma.

Ergang Guo1, Cheng Wu1, Jun Ming1, Wei Zhang1, Linli Zhang1, Guoqing Hu1.   

Abstract

DNA damage repair plays an important role in cancer's initiation and progression, and in therapeutic resistance. The prognostic potential of damage repair indicators was studied in the case of clear cell renal cell carcinoma (ccRCC). Gene expression profiles of the disease were downloaded from cancer genome databases and gene ontology was applied to the DNA repair-related genes. Twenty-six differentially expressed DNA repair genes were identified, and regression analysis was used to identify those with prognostic potential and to construct a risk model. The model accurately predicted patient outcomes and distinguished among patients with different expression levels of immune evasion genes. The data indicate that DNA repair genes can be valuable for predicting the progression of clear cell renal cell carcinoma and the clinical benefits of immunotherapy.
Copyright © 2021 Guo, Wu, Ming, Zhang, Zhang and Hu.

Entities:  

Keywords:  DNA damage; DNA repair; cancer; clear cell renal cell carcinoma; immunotherapy; urology

Year:  2021        PMID: 33488669      PMCID: PMC7820869          DOI: 10.3389/fgene.2020.593039

Source DB:  PubMed          Journal:  Front Genet        ISSN: 1664-8021            Impact factor:   4.599


  61 in total

1.  IL-17C mediates the recruitment of tumor-associated neutrophils and lung tumor growth.

Authors:  C Jungnickel; L H Schmidt; L Bittigkoffer; L Wolf; A Wolf; F Ritzmann; A Kamyschnikow; C Herr; M D Menger; T Spieker; R Wiewrodt; R Bals; C Beisswenger
Journal:  Oncogene       Date:  2017-03-27       Impact factor: 9.867

2.  Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.

Authors:  Triparna Sen; B Leticia Rodriguez; Limo Chen; Carminia M Della Corte; Naoto Morikawa; Junya Fujimoto; Sandra Cristea; Thuyen Nguyen; Lixia Diao; Lerong Li; Youhong Fan; Yongbin Yang; Jing Wang; Bonnie S Glisson; Ignacio I Wistuba; Julien Sage; John V Heymach; Don L Gibbons; Lauren A Byers
Journal:  Cancer Discov       Date:  2019-02-18       Impact factor: 39.397

3.  Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.

Authors:  Robert J Motzer; Bernard Escudier; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Elizabeth R Plimack; Giuseppe Procopio; David F McDermott; Daniel Castellano; Toni K Choueiri; Frede Donskov; Howard Gurney; Stéphane Oudard; Martin Richardet; Katriina Peltola; Ajjai S Alva; Michael Carducci; John Wagstaff; Christine Chevreau; Satoshi Fukasawa; Yoshihiko Tomita; Thomas C Gauler; Christian K Kollmannsberger; Fabio A Schutz; James Larkin; David Cella; M Brent McHenry; Shruti Shally Saggi; Nizar M Tannir
Journal:  Cancer       Date:  2020-07-16       Impact factor: 6.860

4.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

Review 5.  Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis.

Authors:  Arnoud J Templeton; Mairéad G McNamara; Boštjan Šeruga; Francisco E Vera-Badillo; Priya Aneja; Alberto Ocaña; Raya Leibowitz-Amit; Guru Sonpavde; Jennifer J Knox; Ben Tran; Ian F Tannock; Eitan Amir
Journal:  J Natl Cancer Inst       Date:  2014-05-29       Impact factor: 13.506

6.  DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy.

Authors:  Yasser Ged; Joshua L Chaim; Renzo G DiNatale; Andrea Knezevic; Ritesh R Kotecha; Maria I Carlo; Chung-Han Lee; Ashley Foster; Darren R Feldman; Min Yuen Teo; Gopakumar Iyer; Timothy Chan; Sujata Patil; Robert J Motzer; A Ari Hakimi; Martin H Voss
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

7.  Development of a Novel Autophagy-related Prognostic Signature for Serous Ovarian Cancer.

Authors:  Yuanyuan An; Fangfang Bi; Yue You; Xinhui Liu; Qing Yang
Journal:  J Cancer       Date:  2018-10-18       Impact factor: 4.207

8.  Targeting MEK5 impairs nonhomologous end-joining repair and sensitizes prostate cancer to DNA damaging agents.

Authors:  Constantinos G Broustas; Axel J Duval; Kunal R Chaudhary; Richard A Friedman; Renu K Virk; Howard B Lieberman
Journal:  Oncogene       Date:  2020-01-24       Impact factor: 9.867

9.  Development and validation of a hypoxia-immune-based microenvironment gene signature for risk stratification in gastric cancer.

Authors:  Yifan Liu; Jianhua Wu; Weiwei Huang; Shaowen Weng; Baochun Wang; Yiming Chen; Hao Wang
Journal:  J Transl Med       Date:  2020-05-14       Impact factor: 5.531

10.  An elevated neutrophil-to-lymphocyte ratio associates with weight loss and cachexia in cancer.

Authors:  Tyler Barker; Gail Fulde; Bryce Moulton; Lincoln D Nadauld; Terence Rhodes
Journal:  Sci Rep       Date:  2020-05-05       Impact factor: 4.379

View more
  5 in total

1.  Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration.

Authors:  Emily F Higgs; Riyue Bao; Ken Hatogai; Thomas F Gajewski
Journal:  J Immunother Cancer       Date:  2022-06       Impact factor: 12.469

Review 2.  From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma.

Authors:  Jonathan Anker; Justin Miller; Nicole Taylor; Natasha Kyprianou; Che-Kai Tsao
Journal:  Cells       Date:  2021-11-19       Impact factor: 6.600

3.  The clinical significance of epigenetic and RNAPII variabilities occurring in clear cell renal cell carcinoma as a potential prognostic marker.

Authors:  Nóra Ördög; Barbara N Borsos; Hajnalka Majoros; Zsuzsanna Ujfaludi; Gabriella Pankotai-Bodó; Sarolta Bankó; Farkas Sükösd; Levente Kuthi; Tibor Pankotai
Journal:  Transl Oncol       Date:  2022-04-10       Impact factor: 4.803

4.  Pathogenic ATM and BAP1 germline mutations in a case of early-onset, familial sarcomatoid renal cancer.

Authors:  Hannah N Bell; Chandan Kumar-Sinha; Rahul Mannan; Dana Zakalik; Yuping Zhang; Rohit Mehra; Deepa Jagtap; Saravana M Dhanasekaran; Ulka Vaishampayan
Journal:  Cold Spring Harb Mol Case Stud       Date:  2022-04-28

5.  Calcium oxalate crystals trigger epithelial-mesenchymal transition and carcinogenic features in renal cells: a crossroad between kidney stone disease and renal cancer.

Authors:  Paleerath Peerapen; Wanida Boonmark; Pattaranit Putpeerawit; Visith Thongboonkerd
Journal:  Exp Hematol Oncol       Date:  2022-09-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.